The Desk

AI-assisted analysis on every release · Page 167

M&A / Property
AnorTech’s carbon capture partnership marks incremental R&D progress while near-term liquidity depends on closing the Greenland mines deal.

Jun 08, 2026 · 09:00 · ANOR · Anortech Inc. · Routine +

01
Drill Results
Marimaca Copper drilled ultra-high-grade bornite at Pampa Medina, though execution risk and capital intensity cap near-term upside.

Jun 08, 2026 · 08:45 · MARI · Marimaca Copper Corp. · Routine +

02
Other
Performance-based ad tech converts trials to contracts, but revenue remains microscopic relative to burn.

Jun 08, 2026 · 08:31 · BPAI · BrandPilot AI Inc. · Routine +

03
Financings
Treasury liquidation funds debt paydown, but crypto impairments and valuation compression dominate the narrative.

Jun 08, 2026 · 08:31 · HODL · Sol Strategies Inc. · Routine +

04
Production / Operations
Homerun finalizes $9.4 million capital expenditure for the phase one silica purification plant, validating its vertical integration roadmap.

Jun 08, 2026 · 08:31 · HMR · Homerun Resources Inc. · Routine +

05
M&A / Property
Redwood AI's quantum pivot masks dilution risk; stock consolidates near lows after priced-in M&A announcement.

Jun 08, 2026 · 08:30 · AIRX · Redwood AI Corp. · Neutral

06
Drill Results
Operational Milestone Confirmed, But Commerciality Remains the Only True Catalyst

Jun 08, 2026 · 08:30 · RECO · Reconnaissance Energy Africa Ltd. · Routine +

07
M&A / Property
Low-Cost Heavy Oil Asset Acquisition Fuels RF XL 2.0 Commercialization Path Amidst Liquidity Management

Jun 08, 2026 · 08:18 · AXE · Acceleware Ltd. · Routine +

08
Production / Operations
Scaling a cash-pay digital pharmacy model, but liquidity and profitability remain unproven as the stock drifts lower post-IPO.

Jun 08, 2026 · 08:01 · TELY · TELYRX HOLDINGS INC SUBORDINATE VOTING S · Routine +

09
M&A / Property
Late-stage biotech advancing MN-166 across neurology and oncology, with patent wins reinforcing IP moats while pivotal clinical data remains pending.

Jun 08, 2026 · 08:00 · 4875 · NaN · Routine +

10
M&A / Property
AutoCanada’s Calgary collision buy validates turnaround playbook, but retail margins remain the swing factor

Jun 08, 2026 · 08:00 · ACQ · AUTOCANADA INC. · Routine +

11
M&A / Property
Strategic consolidation pivots MAX Power to pure-play natural hydrogen, but execution risk and dilution remain paramount.

Jun 08, 2026 · 08:00 · MAXX · Max Power Mining Corp. · Routine +

12
Regulatory
Psychedelic GMP manufacturer advances ibogaine development amid US policy tailwinds, but commercial revenue remains negligible.

Jun 08, 2026 · 08:00 · OPTI · Optimi Health Corp. · Routine +

13
Other
CCDS Uses Bermuda Conference to Pitch Roll-Up Strategy as Rochester Entry Nears; Dilution and Integration Risks Remain

Jun 08, 2026 · 08:00 · CCDS · Carrier Connect Data Solutions Inc. · Routine +

14
Other
TD's latest consumer survey highlights fraud stigma but carries no direct financial or operational impact.

Jun 08, 2026 · 08:00 · TD · TORONTO-DOMINION BANK (THE) · Neutral

15

← Newer Older →

The Desk

AnorTech’s carbon capture partnership marks incremental R&D progress while near-term liquidity depends on closing the Greenland mines deal.

Marimaca Copper drilled ultra-high-grade bornite at Pampa Medina, though execution risk and capital intensity cap near-term upside.

Performance-based ad tech converts trials to contracts, but revenue remains microscopic relative to burn.

Treasury liquidation funds debt paydown, but crypto impairments and valuation compression dominate the narrative.

Homerun finalizes $9.4 million capital expenditure for the phase one silica purification plant, validating its vertical integration roadmap.

Redwood AI's quantum pivot masks dilution risk; stock consolidates near lows after priced-in M&A announcement.

Operational Milestone Confirmed, But Commerciality Remains the Only True Catalyst

Low-Cost Heavy Oil Asset Acquisition Fuels RF XL 2.0 Commercialization Path Amidst Liquidity Management

Scaling a cash-pay digital pharmacy model, but liquidity and profitability remain unproven as the stock drifts lower post-IPO.

Late-stage biotech advancing MN-166 across neurology and oncology, with patent wins reinforcing IP moats while pivotal clinical data remains pending.

AutoCanada’s Calgary collision buy validates turnaround playbook, but retail margins remain the swing factor

Strategic consolidation pivots MAX Power to pure-play natural hydrogen, but execution risk and dilution remain paramount.

Psychedelic GMP manufacturer advances ibogaine development amid US policy tailwinds, but commercial revenue remains negligible.

CCDS Uses Bermuda Conference to Pitch Roll-Up Strategy as Rochester Entry Nears; Dilution and Integration Risks Remain

TD's latest consumer survey highlights fraud stigma but carries no direct financial or operational impact.